In a lipopolysaccharide-induced neutrophilic CRSwNP mouse model, blocking IL-1β activity with an IL-1β receptor antagonist significantly reduced the number of IDO1+ fibroblasts and alleviated nasal inflammation (41). This evidence concerns the gene IDO1 and chronic rhinosinusitis with nasal polyps.